Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIBUTE: Tildrakizumab in Moderate-Severe Chronic Plaque Psoriasis
NCT04229836Phase 4Completed
- Sponsor
- Almirall
- Start
- Dec 2019
- Primary completion
- Nov 2021
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 4 trial of tildrakizumab in plaque psoriasis, sponsored by Almirall. Started Dec 2019; status: completed.
02
Drugs
tildrakizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04229836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04229836.